Acyldepsipeptide analogues: A future generation antibiotics for Tuberculosis treatment

Thumbnail Image

Files

cobongela_acyldepsiptide analogues_2022.pdf (1.34 MB)

Date

2022

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI

Abstract

Acyldepsipeptides (ADEPs) are a new class of emerging antimicrobial peptides (AMPs), which are currently explored for treatment of pathogenic infections, including tuberculosis (TB). These cyclic hydrophobic peptides have a unique bacterial target to the conventional anti-TB drugs, and present a therapeutic window to overcome Mycobacterium Tuberculosis (M. tb) drug resistance. ADEPs exerts their antibacterial activity on M. tb strains through activation of the protein homeostatic regulatory protease, the caseinolytic protease (ClpP1P2). ClpP1P2 is normally regulated and activated by the ClpP-ATPases to degrade misfolded and toxic peptides and/or short proteins. ADEPs bind and dysregulate all the homeostatic capabilities of ClpP1P2 while inducing non-selective proteolysis. The uncontrolled proteolysis leads to M. tb cell death within the host.

Description

Keywords

Acyldepsipeptides, Antimicrobial peptides, Tuberculosis, Mycobacterium tuberculosis, Pharmaceutics

Citation

Cobongela, S. Z. Z. et al. (2022). Acyldepsipeptide analogues: A future generation antibiotics for Tuberculosis treatment. Pharmaceutics, 14(9),1956. https://doi.org/10.3390/pharmaceutics14091956

URI

https://doi.org/10.3390/pharmaceutics14091956
 http://hdl.handle.net/10566/8036

Collections

Research Articles (Biotechnology)